Original Articles
Sex Differences in Outcome with Bevacizumab Therapy: Analysis of Patients with Advanced-Stage Non-small Cell Lung Cancer Treated with or without Bevacizumab in Combination with Paclitaxel and Carboplatin in the Eastern Cooperative Oncology Group Trial 4599

https://doi.org/10.1097/JTO.0b013e3181fa8efdGet rights and content
Under an Elsevier user license
open archive

Introduction:

E4599 compared carboplatin and paclitaxel with (PCB) or without (PC) bevacizumab in patients with advanced-stage non-small cell lung cancer. Bevacizumab improved overall survival. However, an unplanned subset analysis did not show a survival benefit for females treated with bevacizumab.

Methods:

Known prognostic factors and toxicities were compared by sex. Proportional hazards models of survival with multiple factor combinations were used to adjust for treatment effect.

Results:

The analysis includes 850 patients. The median survival was 8.7 months (PC) versus 11.7 months (PCB) for males (p = 0.001) and 13.1 months (PC) versus 13.3 months (PCB) for females (p = 0.87). Progression-free survival and response rate on the PCB arm were 6.3 months and 29% for males and 6.2 months and 41% for females (p > 0.05). Progression-free survival and response rate on the PC arm were 4.3 months and 16% for males and 5.3 months and 14% for females (p > 0.05). No significant demographic differences were seen between the two arms for males, whereas fewer females on the PCB arm had liver metastasis (PCB 11.7% versus PC 23.2%, p = 0.003). Adverse events with a sex difference on the PCB arm included severe hypertension (males: 4.2%, females: 9.9%, p = 0.02), constipation (males: 1.4%, females: 4.7%, p = 0.05), and abdominal pain (males: 0.9%, females: 5.2%, p = 0.01). In the proportional hazards model adjusting for the other factors, the test for a sex by treatment interaction was not significant (p = 0.09).

Conclusions:

Multiple factors may contribute to the apparent sex-specific differences in efficacy of bevacizumab noted in this study.

Key Words:

Non-small cell lung cancer
Sex differences
Bevacizumab

Cited by (0)

Disclosure: Alan B. Sandler serves as a consultant for and has received honoraria and research funding from Genentech. Julie R. Brahmer serves as a consultant for Genentech. Joan Schiller serves as a consultant for and has received research funding from Genentech. Robert Gray has received research funding from Genentech.

This study was coordinated by the Eastern Cooperative Oncology Group (Robert L. Comis, MD, Chair). The contents of the article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.